What is Neuragain?
Neuragain specializes in providing IV ketamine therapy, a cutting-edge treatment for depression and anxiety disorders. The company is committed to building a national network of highly skilled psychiatric professionals who deliver effective, non-addictive solutions for chronic pain and mental health challenges. Since its establishment in 2013, Neuragain has cultivated a strong reputation for exceptional patient care and a high success rate in addressing treatment-resistant conditions. By prioritizing evidence-based methodologies, Neuragain aims to enhance the quality of life for individuals who have not found relief through conventional therapeutic approaches.
How much funding has Neuragain raised?
Neuragain has raised a total of $56K across 1 funding round:
Debt
$56K
Debt (2021): $56K with participation from PPP
Key Investors in Neuragain
PPP
Public-Private Partnership
What's next for Neuragain?
The recent influx of substantial expansion capital positions Neuragain for significant growth and network scaling. As a company operating at a significant Series B/C stage, this funding is likely to be strategically deployed to enhance operational capacity, expand its geographical reach, and potentially invest in further research and development to refine its ketamine therapy protocols. The focus on building a national network of psychiatric professionals suggests a strategic imperative to standardize care quality and accessibility across its facilities, thereby solidifying its leadership in the mental health treatment market.
See full Neuragain company page
